Clinical trials
Metastatic Tumor clinical trials
Below are recruiting metastatic tumor clinical trials, each written for real people, not researchers. We’re tracking 587 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07089550Recruiting
PSMA PET scans to track treatment response in advanced prostate cancer
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Bologna, ItalyAges 18 years+ - NCT06088472RecruitingPhase 1
TIL therapy for advanced solid tumors
This trial tests a treatment made from your own immune cells (TILs) that are taken from a tumor, grown in a lab, and then given back to you to fight cancer. It's for people with solid tumors that have spread or come back after treatment.
Xuzhou, JiangsuAges 18–70 - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+ - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06023212RecruitingPhase 1/Phase 2
Tranexamic acid to prevent bleeding in spine surgery for lung cancer
This trial tests if a medicine called tranexamic acid can help reduce bleeding during surgery for lung cancer that has spread to the spine. It may be an option if you have a single tumor in your spine and are having separation surgery.
Hangzhou, ZhejiangAges 10–80 - NCT07238075RecruitingPhase 1
ADCX-020 for advanced or metastatic cancers
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
Sydney, New South WalesAges 18 years+ - NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT07132190RecruitingPhase 2
Radiation for growing brain tumors with same-day planning
This study tests whether a precise, one-day radiation treatment for brain tumors that are growing or in tricky spots can be effective with a smaller safety margin. It's designed for people whose brain tumors are changing quickly or sitting near areas of swelling or recent surgery.
Boston, MassachusettsAges 18 years+ - NCT00722228RecruitingPhase 1/Phase 2
Cancer vaccine made from your cells or a donor
This early-phase trial tests a whole-cell cancer vaccine for people with certain metastatic cancers. It aims to help your immune system recognize and fight the cancer, especially when prior chemotherapy hasn’t worked.
JerusalemAges 18 years+ - NCT06638034RecruitingEarly Phase 1
New imaging and radiation therapy for metastatic tumors
This trial tests a new type of imaging scan and treatment for cancers that have spread. You would first have two special scans, then you may receive a targeted radiation therapy (177Lu-FAPI-RGD) to see if it can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–90 - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Aurora, ColoradoAges 12–39 - NCT05733949RecruitingEarly Phase 1
Targeted radiation for people with many solid tumor metastases
This trial tests a precise type of radiation that targets multiple tumor spots in a carefully planned way. It may help people with many metastatic (spread) solid tumors when standard treatments aren’t working or can’t be used.
Duarte, CaliforniaAges 18 years+ - NCT05400967RecruitingEarly Phase 1
Scan metastatic tumors and test targeted radiation treatment
This trial looks at whether a special PET scan can find metastatic tumors and guide a targeted radiation treatment. It may help people by improving how doctors locate tumors and decide where to deliver therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Chuo Ku, TokyoAges 18 years+ - NCT06771219RecruitingPhase 1
Testing SLV-154 for advanced cancers
This trial tests a new drug called SLV-154 for people whose advanced cancer has not responded to standard treatments. The goal is to see if SLV-154 can shrink tumors or slow cancer growth.
Newport Beach, CaliforniaAges 12 years+ - NCT04243720Recruiting
Study of immune resistance after immunotherapy
This trial studies why some solid cancers stop responding to immune-based drugs (like anti–PD-1/PD-L1) and what can be done next. You may be eligible if your cancer has progressed after immunotherapy and you can safely undergo a tumor needle biopsy.
Toronto, OntarioAges 18 years+ - NCT05351502RecruitingPhase 1
Nitric oxide injection for solid tumors that can’t be removed
This Phase 1 study tests whether injecting nitric oxide into certain solid tumors is safe and may help shrink tumors that cannot be removed with surgery. It includes adults with measurable, treatment-resistant skin or under-skin (cutaneous or subcutaneous) tumors and checks for side effects and early signs of benefit.
BeershebaAges 18 years+ - NCT07001085Recruiting
Blood test to monitor liver cancer after surgery
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Warsaw, Masovian VoivodeshipAges 18–75 - NCT07269080RecruitingPhase 1
Radiation plus immunotherapy for advanced solid tumors
This trial tests whether adding targeted radiation to your metastatic tumors can help your immunotherapy work better. It is for people with advanced solid tumors that have spread to 3-10 spots and who have been on immunotherapy for at least 3 months.
Chicago, IllinoisAges 18 years+ - NCT01891318RecruitingPhase 1/Phase 2
Study radiosurgery plus surgery for brain metastases
This trial tests giving focused radiation (radiosurgery) before surgery for certain resectable brain metastases. It may help shrink or control tumors in the brain before they are surgically removed.
Cleveland, OhioAges 18 years+ - NCT07492680RecruitingPhase 2
Study of BMS-986504 for solid tumors with MTAP deletion
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
San Francisco, CaliforniaAges 18 years+ - NCT05842785RecruitingPhase 1/Phase 2
Study drug for hard-to-treat advanced solid cancers or lymphomas
This early-phase study tests TSN222 in people with advanced, hard-to-treat solid tumors or lymphomas. It aims to see whether the drug can shrink tumors or improve outcomes, including in specific cancer types like head and neck cancer and melanoma.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT06365840RecruitingPhase 2
Study of IMC-001 for advanced tumors with high mutations
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
GoyangAges 19 years+
Hear when a new Metastatic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic tumor?
- Yes. Clin2 currently lists 587 recruiting metastatic tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.